Tag: allergy

AMF Regulated Information
Châtillon, France, July 6, 2026

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

新一届领导层正式履职，全球过敏领域学界持续推进“零负担愿景”目标，致力于实现一个无过敏与无哮喘病痛的未来

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

Réunis à Istanbul, des spécialistes de renom en allergologie exploreront les moyens par lesquels la science, la prévention et les politiques peuvent réduire l’impact mondial des maladies allergiques

Führende Allergieexperten treffen sich in Istanbul, um zu erörtern, wie Wissenschaft, Prävention und Politik die weltweiten Auswirkungen allergischer Erkrankungen verringern können

מומחי אלרגיה מובילים יתכנסו באיסטנבול כדי לבחון כיצד מדע, מניעה ומדיניות יכולים להפחית את ההשפעה הגלובלית של מחלות אלרגיות.

Para ahli energi terkemuka berkumpul di Istanbul untuk membahas secara lebih mendalam bagaimana sains, pencegahan, dan kebijakan dapat mengurangi dampak penyakit alergi di tingkat global